-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Sell on Silence Therapeutics, Lowers Price Target to $3

Benzinga·05/09/2025 18:13:56
Listen to the news
Goldman Sachs analyst Richard Law maintains Silence Therapeutics (NASDAQ:SLN) with a Sell and lowers the price target from $4 to $3.